Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEVACOR vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
Primary hypercholesterolemia,Mixed dyslipidemia,Homozygous familial hypercholesterolemia,Prevention of coronary heart disease,Slow progression of coronary atherosclerosis
Moderate to severe pain where an opioid analgesic is appropriate
10-80 mg orally once daily in the evening.
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
The terminal elimination half-life of lovastatin is approximately 1-2 hours for the parent drug. However, the active metabolite (lovastatin acid) has a half-life of about 1.7-2.6 hours. Despite the short half-life, the duration of HMG-Co A reductase inhibition is prolonged due to enterohepatic recirculation and tissue distribution. Once-daily dosing is effective for LDL-C reduction.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours.
Primarily hepatic via CYP3A4 isoenzyme; significant first-pass metabolism.
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI).
Lovastatin is primarily excreted via the biliary/fecal route (approximately 80-85% of the absorbed dose) as metabolites. Renal excretion accounts for about 10% of the administered dose, mostly as metabolites; less than 5% is excreted unchanged in urine.
Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%).
Lovastatin and its active metabolite are extensively bound to plasma proteins, with binding >95% for the parent drug and >92% for lovastatin acid. The primary binding protein is albumin.
Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein).
The apparent volume of distribution (Vd) for lovastatin is approximately 0.3-0.6 L/kg, indicating distribution into tissues, but predominantly into the liver (the primary site of action). High Vd reflects extensive tissue binding.
Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution).
Oral bioavailability of lovastatin is low, approximately 5% for the parent drug due to extensive first-pass metabolism in the liver. The active metabolite (lovastatin acid) is formed via hydrolytic metabolism. Food increases absorption, so it is recommended to be taken with the evening meal.
Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%.
No dose adjustment required for GFR >30 m L/min; if GFR <30 m L/min, start at 5 mg/day and increase cautiously.
Cr Cl 30-50 m L/min: use with caution; decrease dose interval to every 6 hours if needed. Cr Cl <30 m L/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis.
Contraindicated in active liver disease or unexplained transaminase elevations; Child-Pugh Class A/B: use with caution, no specific dose adjustment; Child-Pugh Class C: contraindicated.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation.
For heterozygous familial hypercholesterolemia: 10-20 mg orally once daily in the evening for ages 10-17; adjust based on response.
Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg).
Start at lower end of dosing range (10 mg/day) due to increased risk of myopathy; titrate cautiously.
Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen.
No FDA black box warning.
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
Myopathy/rhabdomyolysis risk increased with high doses or concomitant use of CYP3A4 inhibitors,Hepatic enzyme elevations; monitor liver function tests,Avoid use in patients with active liver disease or unexplained persistent transaminase elevations,Use caution in patients with predisposing factors for renal failure
Respiratory depression risk, especially in patients with compromised respiratory function,Potential for opioid dependence, abuse, and misuse,Risk of withdrawal if discontinued abruptly after prolonged use,Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists,Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease,Central nervous system depression additive with other CNS depressants,Elderly or debilitated patients may have increased sensitivity to effects,May cause hypotension, especially in hypovolemic patients,Serotonin syndrome risk when used with serotonergic drugs,Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects
Active liver disease,Unexplained persistent elevations of serum transaminases,Hypersensitivity to any component of the product,Pregnancy,Lactation
Hypersensitivity to either component,Severe respiratory depression (e.g., acute asthma, hypercapnia),Acute or severe bronchial asthma,Suspected surgical abdomen (may obscure diagnosis),Monoamine oxidase inhibitor (MAOI) use (current or within 14 days),Severe hepatic impairment or active liver disease (acetaminophen component),Known or suspected gastrointestinal obstruction (including paralytic ileus)
Grapefruit juice inhibits CYP3A4 and increases lovastatin levels, increasing risk of myopathy/rhabdomyolysis; avoid concurrent intake. High-fat meals enhance absorption; take with evening meal to optimize efficacy.
Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs.
Pregnancy Category X. Contraindicated in all trimesters due to risk of fetal skeletal muscle damage, CNS abnormalities, and cardiac defects. Case reports of limb defects, cleft palate, and fetal death.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term.
Contraindicated. Excreted into human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants, including interference with cholesterol biosynthesis.
Acetaminophen: Excreted in low amounts (M/P ratio ~0.2-0.9); compatible with breastfeeding. Pentazocine: Excreted in breast milk; M/P ratio unknown; may cause CNS effects in infants. Use with caution, especially in neonates or premature infants. Monitor infant for sedation and respiratory depression.
Not applicable; contraindicated in pregnancy. No dose adjustments recommended as drug should be discontinued prior to conception or immediately upon pregnancy detection.
Acetaminophen: No significant pharmacokinetic changes in pregnancy; standard dosing (max 3-4 g/day) applies. Pentazocine: Clearance may increase due to enhanced hepatic metabolism; dose adjustments not routinely recommended but monitor response. Avoid high doses near term due to risk of neonatal depression.
MEVACOR (lovastatin) is a prodrug that requires CYP3A4 metabolism; avoid coadministration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, erythromycin, clarithromycin, protease inhibitors, nefazodone, grapefruit juice). Titrate dose based on LDL-C response; start at 20 mg daily with evening meal. Monitor liver function tests at initiation and as clinically indicated; contraindicated in active liver disease or unexplained transaminase elevations. Increased risk of myopathy/rhabdomyolysis with concurrent fibrates (especially gemfibrozil), niacin (>1 g/day), and CYP3A4 inhibitors. Use cautiously in patients with renal impairment.
Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential.
Take this medication with the evening meal to enhance absorption and reduce side effects.,Avoid consuming grapefruit or grapefruit juice while taking this drug, as it can increase the risk of side effects.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Do not take over-the-counter niacin or other cholesterol-lowering medications without consulting your healthcare provider.,Inform your doctor about all other medications, including herbal supplements and over-the-counter drugs.,Adhere to a heart-healthy diet and exercise regimen as prescribed by your healthcare provider.,Adverse effects may include headache, abdominal pain, and nausea; contact your doctor if severe or persistent.
Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications).,Avoid alcohol while taking this medication; risk of liver damage increases.,This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known.,Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine).,Do not suddenly stop if used long-term; withdrawal symptoms may occur.,If you have opioid dependence, this medication may precipitate withdrawal symptoms.,This medication may cause constipation; maintain fluid and fiber intake.
No interactions on record
"Pentazocine, a mixed opioid agonist-antagonist, may attenuate the central nervous system (CNS) stimulant effects of dextroamphetamine by competitively blocking mu-opioid receptors and potentially altering dopamine release, leading to reduced analgesic efficacy of pentazocine and diminished therapeutic response to dextroamphetamine in treating attention deficit hyperactivity disorder (ADHD) or narcolepsy. This interaction can result in suboptimal pain control and exacerbation of ADHD symptoms, requiring dose adjustments or alternative therapies."
"The concurrent use of ipratropium, an anticholinergic agent, and pentazocine, a mixed opioid agonist-antagonist, may lead to an increased risk of central nervous system (CNS) depression and anticholinergic adverse effects. Pentazocine can enhance the sedative and respiratory depressant effects of ipratropium, while ipratropium may potentiate pentazocine's anticholinergic actions, such as dry mouth, blurred vision, constipation, and urinary retention. Clinically, this interaction can result in excessive sedation, confusion, and impaired cognitive and motor function, particularly in elderly or debilitated patients."
"The combination of pentazocine, a mixed agonist-antagonist opioid, with triazolam, a benzodiazepine, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and psychomotor impairment. This is due to the synergistic effects of both drugs on GABAergic and opioid receptors in the brainstem and cortex. Clinically, this may result in excessive drowsiness, confusion, ataxia, and an elevated risk of falls or respiratory compromise, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEVACOR vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
MEVACOR is a HMG-CoA Reductase Inhibitor (Statin) that works by Competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEVACOR and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEVACOR is: 10-80 mg orally once daily in the evening.. The standard adult dose of ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is: One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEVACOR and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEVACOR is classified as Category C. Pregnancy Category X. Contraindicated in all trimesters due to risk of fetal skeletal muscle damage, CNS abnormalities, and cardiac defects. Case reports of limb defects, cleft pal. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.